Literature DB >> 1718777

Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleotides in vitro and in vivo.

R S Goody1, B Müller, T Restle.   

Abstract

Arguments are presented leading to the conclusion that two major factors contribute to the potency of inhibition of DNA-polymerase activity by chain-terminating nucleotides. The relative significance of these factors varies with the reaction conditions, particularly with the length of the template and the concentration ratio of enzyme (reverse transcriptase or other DNA polymerase) to primer. It is concluded that potent inhibition of HIV-reverse transcriptase activity under typical in vitro and in vivo conditions arises from different features of the interaction of chain terminators with the enzyme. A new method of testing for the parameter important under in vivo conditions is suggested.

Mesh:

Substances:

Year:  1991        PMID: 1718777     DOI: 10.1016/0014-5793(91)81089-q

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  30 in total

Review 1.  Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.

Authors:  Nicolas Sluis-Cremer; N Alpay Temiz; Ivet Bahar
Journal:  Curr HIV Res       Date:  2004-10       Impact factor: 1.581

2.  Nucleotide-dependent conformational change governs specificity and analog discrimination by HIV reverse transcriptase.

Authors:  Matthew W Kellinger; Kenneth A Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

3.  New HIV Drugs in Development, 2005.

Authors:  Jeffrey P Nadler; Michael C Phillips
Journal:  Curr Infect Dis Rep       Date:  2005-05       Impact factor: 3.725

4.  Bifunctional inhibition of human immunodeficiency virus type 1 reverse transcriptase: mechanism and proof-of-concept as a novel therapeutic design strategy.

Authors:  Christopher M Bailey; Todd J Sullivan; Pinar Iyidogan; Julian Tirado-Rives; Raymond Chung; Juliana Ruiz-Caro; Ebrahim Mohamed; William L Jorgensen; William Jorgensen; Roger Hunter; Karen S Anderson
Journal:  J Med Chem       Date:  2013-05-09       Impact factor: 7.446

5.  Ab initio molecular dynamics studies on HIV-1 reverse transcriptase triphosphate binding site: implications for nucleoside-analog drug resistance.

Authors:  F Alber; P Carloni
Journal:  Protein Sci       Date:  2000-12       Impact factor: 6.725

6.  Bifunctional inhibition of HIV-1 reverse transcriptase: a first step in designing a bifunctional triphosphate.

Authors:  Dongyuan Piao; Aravind Basavapathruni; Pinar Iyidogan; Guangxiu Dai; Wolfgang Hinz; Adrian S Ray; Eisuke Murakami; Joy Y Feng; Fei You; Ginger E Dutschman; David J Austin; Kathlyn A Parker; Karen S Anderson
Journal:  Bioorg Med Chem Lett       Date:  2012-12-20       Impact factor: 2.823

Review 7.  A mechanistic view of human mitochondrial DNA polymerase gamma: providing insight into drug toxicity and mitochondrial disease.

Authors:  Christopher M Bailey; Karen S Anderson
Journal:  Biochim Biophys Acta       Date:  2010-01-18

8.  The "Connection" Between HIV Drug Resistance and RNase H.

Authors:  Krista A Delviks-Frankenberry; Galina N Nikolenko; Vinay K Pathak
Journal:  Viruses       Date:  2010-07-01       Impact factor: 5.048

9.  Novel high-throughput screen identifies an HIV-1 reverse transcriptase inhibitor with a unique mechanism of action.

Authors:  Chih-Wei Sheen; Onur Alptürk; Nicolas Sluis-Cremer
Journal:  Biochem J       Date:  2014-09-15       Impact factor: 3.857

10.  Characterization of novel non-nucleoside reverse transcriptase (RT) inhibitor resistance mutations at residues 132 and 135 in the 51 kDa subunit of HIV-1 RT.

Authors:  Dwight V Nissley; Jessica Radzio; Zandrea Ambrose; Chih-Wei Sheen; Noureddine Hamamouch; Katie L Moore; Gilda Tachedjian; Nicolas Sluis-Cremer
Journal:  Biochem J       Date:  2007-05-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.